natgillin/translations-raw huggingface dataset:
Epoxide hydrolase inhibitors (e.g. valproic acid, valpromide) Inhibitors of microsomal Epoxide Hydrolase (mEH) (e.g. valproic acid, valpromide) may interfere with the metabolism of lesinurad.
Inhibitori epoksid hidrolaze (npr. valproatna kiselina, valpromid) Inhibitori mikrosomalne epoksid hidrolaze (mEH) (npr. valproatna kiselina, valpromid) mogu utjecati na metabolizam lesinurada.
The most common adverse reaction leading to discontinuation of lesinurad was blood creatinine increased (frequency 0.8%).
Najčešća nuspojava koja je dovela do prekida primjene lesinurada bila je povišen kreatinin u krvi (učestalost 0,8%).
Gout is a type of arthritis caused by the build-up of uric acid crystals around the joints.
Giht je vrsta artritisa uzrokovana nakupljanjem kristala mokraćne kiseline u zglobovima.
If the patient is a known carrier of HLA-B*5801, especially in those who are of Han Chinese, Thai or Korean descent, allopurinol should not be started unless there are no other reasonable therapeutic options and the benefits are thought to exceed risks.
Ako je poznato da je bolesnik nositelj alela HLA-B*5801, pogotovo u bolesnika Han kineskog, Thai ili korejskog porijekla, liječenje alopurinolom ne smije se započeti osim ako ne postoje druge razumne terapijske mogućnosti i smatra se da koristi premašuju rizike.
There are no data from the use of lesinurad and limited amount of data from the use of allopurinol in pregnant women.
Nema podataka o primjeni lesinurada u trudnica, a podaci o primjeni alopurinola u trudnica su ograničeni.
Hydroxypropylcellulose Microcrystalline cellulose Lactose monohydrate Crospovidone Magnesium stearate
Jezgra tablete hidroksipropilceluloza mikrokristalična celuloza laktoza hidrat krospovidon magnezijev stearat
Inhibition of the metabolism of theophylline by allopurinol has been reported.
Prijavljena je inhibicija metabolizma teofilina alopurinolom.
For allopurinol, undesirable effects may vary in their incidence depending on the dose received and also when given in combination with other medicinal products.
Za alopurinol, nuspojave mogu varirati u svojoj incidenciji ovisno o primljenoj dozi te također kada se taj lijek daje u kombinaciji s drugim lijekovima.
Therefore effective inhibition of xanthine oxidase is maintained over a 24 hour period with a single daily dose of allopurinol.
Stoga se djelotvorna inhibicija ksantin oksidaze održava tijekom 24-satnog razdoblja pomoću jedne doze alopurinola jedanput dnevno.
Male infertility, erectile dysfunction, gynaecomastia
Muška neplodnost, erektilna disfunkcija, ginekomastija
Additional monitoring of lipids and blood pressure is recommended in patients using sensitive CYP3A substrate lipid lowering medicinal products (such as lovastatin or simvastatin) or antihypertensive medicinal products (such as amlodipine, felodipine or nisoldipine), since their efficacy may be reduced (see section 4.5).
Preporučuje se dodatno praćenje lipida i krvnog tlaka u bolesnika koji uzimaju lijekove koji su osjetljivi supstrati CYP3A za sniženje lipida (poput lovastatina ili simvastatina) ili sniženje krvnog tlaka (poput amlodipina, felodipina ili nisoldipina), s obzirom da njihova djelotvornost može biti smanjena (vidjeti dio 4.5).
In male and female rats, there was no effect on mating or fertility with lesinurad.
U mužjaka i ženki štakora, primjena lesinurada nije imala učinak na parenje ili plodnost.
The choice of the dose strength of Duzallo depends on the allopurinol dose already taken as individual tablet(s) and will be decided by your doctor.
Odabir jačine doze lijeka Duzallo ovisi o dozi alopurinola koji se već uzima kao pojedinačna(e) tableta(e), a o odabiru će odlučiti Vaš liječnik.
In clinical trials, most adverse reactions were mild or moderate in intensity and resolved while continuing lesinurad therapy.
U kliničkim ispitivanjima, većina je nuspojava bila blagog do umjerenog intenziteta i razriješena je uz nastavak liječenja lesinuradom.
In the same trials, all patients with a MACE treated with lesinurad 200 mg had a history of heart failure, stroke or myocardial infarction.
U istim ispitivanjima svi bolesnici koji su imali MACE i liječeni su lesinuradom u dozi od 200 mg, imali su u anamnezi zatajenje srca, moždani udar ili infarkt miokarda.
Allopurinol can increase the plasma concentration of ciclosporin when concomitantly administered.
Alopurinol može povećati koncentraciju ciklosporina u plazmi kod istodobne primjene.
Chlorpropamide
Klorpropamid
Rash and skin symptoms
Osip i kožni simptomi
The other ingredients are: - tablet core: hydroxypropylcellulose, microcrystalline cellulose, lactose monohydrate, crospovidone, magnesium stearate - film-coating: hypromellose, titanium dioxide (E171), triacetin, iron oxide yellow (E172), iron oxide red (E172)
Drugi sastojci su: - jezgra tablete: hidroksipropilceluloza, mikrokristalična celuloza, laktoza hidrat, krospovidon, magnezijev stearat - film-ovojnica: hipromeloza, titanijev dioksid (E171), triacetin, željezov oksid žuti (E172), željezov oksid crveni (E172)
Vidarabine (Adenine Arabinoside)
Vidarabin (adenin arabinozid)
Lesinurad is a mild to moderate inducer of CYP3A and therefore may lower plasma concentrations of some hormonal contraceptives, thereby decreasing contraceptive effectiveness (see sections 4.4 and
Lesinurad je blagi do umjereni induktor CYP3A i prema tome može sniziti koncentracije nekih hormonskih kontraceptiva u plazmi te time smanjiti učinkovitost kontracepcije (vidjeti dijelove 4.4 i 4.6).
If aluminium hydroxide is taken concomitantly, allopurinol-containing medicinal products may have an attenuated effect.
Ako se istodobno uzima aluminijev hidroksid, lijekovi koji sadrže alopurinol mogu imati oslabljen učinak.
Renal function should be evaluated prior to initiation of Duzallo and monitored periodically thereafter (e. g. 4 times per year), based on clinical considerations, such as baseline renal function, volume depletion, concurrent illness or concomitant medicinal products.
Potrebno je procijeniti funkciju bubrega prije početka primjene lijeka Duzallo, te je redovito pratiti tijekom liječenja (npr. 4 puta godišnje), na temelju kliničkih okolnosti poput početne vrijednosti funkcije bubrega, deplecije volumena, istodobno prisutne bolesti ili istodobno primjenjivanih lijekova.
Patients taking Duzallo which contains the active substance allopurinol and 6mercaptopurine or azathioprine must reduce their dose to 25 % of the intended dose of 6
Bolesnici koji uzimaju Duzallo, koji sadrži djelatnu tvar alopurinol, i 6-merkaptopurin ili azatioprin moraju smanjiti njihovu dozu na 25% namijenjene doze 6-merkaptopurina ili azatioprina.
Iron oxide yellow (E172) Iron oxide red (E172)
Ovojnica tablete hipromeloza titanijev dioksid (E171) triacetin željezov oksid žuti (E172) željezov oksid crveni (E172)
Pale pink oblong film-coated tablets with 7 x 17 mm in size.
Blijedo ružičaste, duguljaste, filmom obložene tablete veličine 7 x 17 mm.
In animal studies, long-term use of high allopurinol doses resulted in formation of xanthine precipitates, which led to changes in the urinary tract.
U ispitivanjima na životinjama dugotrajna primjena visokih doza alopurinola rezultirala je stvaranjem precipitata ksantina, koji je doveo do promjena u mokraćnom sustavu.
Stevens-Johnson syndrome, toxic epidermal necrolysis, angioedema, medicinal product eruption, alopecia, hair colour changes
Stevens-Johnsonov sindrom, toksična epidermalna nekroliza, angioedem, izbijanje kožnih promjena uzrokovano lijekom, alopecija, promjene boje kose
The main metabolite of allopurinol is oxypurinol.
Glavni metabolit alopurinola je oksipurinol.
It is used to treat gout in adult patients in case allopurinol alone is not controlling your gout.
Primjenjuje se za liječenje gihta u odraslih bolesnika ako alopurinol koji uzimate samog, ne kontrolira Vaš giht.
Nausea, vomiting and diarrhoea
Mučnina, povraćanje i dijareja
A possible interaction should be taken into account when a patient on oral anticoagulants is given Duzallo.
Potrebno je uzeti u obzir moguću interakciju, kada se Duzallo daje bolesniku koji prima oralne antikoagulanse.
Duzallo may cause serious kidney problems (see section 4).
Duzallo može uzrokovati ozbiljne probleme s bubrezima (vidjeti dio 4).
The most frequent renal-related adverse reaction was blood creatinine increased (3.7% with lesinurad 200 mg compared to 2.2% with placebo).
Najčešća nuspojava povezana s bubrezima bila je povišena razina kreatinina u krvi (3,7% za lesinurad u dozi od 200 mg u usporedbi s 2,2% za placebo).
--o-- Placebo + Allopurinol,
Terapijska skupina: --o-- placebo + alopurinol,
Do not take Duzallo if: - you are allergic to allopurinol, lesinurad or any of the other ingredients of this medicine (listed in section 6) - you have tumour lysis syndrome - a fast breakdown of cancer cells which can cause high uric acid levels - you have Lesch-Nyhan syndrome - a rare inherited illness that starts in childhood where there is too much uric acid in the blood - your kidneys work very poorly or you have end stage kidney disease (when the kidneys no longer work well enough to meet the body's need) - you have received a kidney transplant - you are on kidney dialysis.
Nemojte uzimati Duzallo: - ako ste alergični na alopurinol, lesinurad ili neki drugi sastojak ovog lijeka (naveden u dijelu 6) - ako imate sindrom lize tumora - brzi raspad stanica raka koji može uzrokovati visoke razine mokraćne kiseline - ako imate Lesch-Nyhanov sindrom - rijetku nasljednu bolest koja počinje u djetinjstvu kada postoji previše mokraćne kiseline u krvi - ako Vaši bubrezi rade jako slabo ili imate završni stadij bolesti bubrega (kada bubrezi više ne rade dovoljno dobro za odgovaranje na potrebe tijela) - ako Vam je transplantiran bubreg - ako ste na dijalizi bubrega.
The serious adverse reactions renal failure, renal impairment and nephrolithiasis have occurred uncommonly (less than 1 case per 100 patients) (see Table 1).
Ozbiljne nuspojave: zatajenje bubrega, oštećenje funkcije bubrega i nefrolitijaza javile su se manje često (manje od jedan slučaj na 100 bolesnika) (vidjeti Tablicu 1).
Female patients of childbearing age should practice additional methods of contraception and not rely on hormonal contraception alone when taking Duzallo (see sections 4.5 and 4.6).
Bolesnice reproduktivne dobi moraju koristiti dodatne metode kontracepcije i ne smiju se pouzdati samo na hormonsku kontracepciju tijekom uzimanja lijeka Duzallo (vidjeti dijelove 4.5 i 4.6).
Allopurinol and oxypurinol clearance is greatly reduced in patients with poor renal function resulting in higher plasma levels in chronic therapy.
Klirens alopurinola i oksipurinola značajno je smanjen u bolesnika sa slabom funkcijom bubrega što rezultira višim razinama u plazmi tijekom kronične terapije.
Duzallo contains lesinurad and allopurinol, two anti-hyperuricemic active substances with complimentary mechanisms of actions.
Duzallo sadrži lesinurad i alopurinol, dvije djelatne tvari protiv hiperuricemije i s komplementarnim mehanizmima djelovanja.
Post-hoc analyses in a subgroup of patients with high cardiovascular risk at baseline (as defined by transient ischemic attack, angina pectoris, heart failure, myocardial infarction, peripheral vascular disease and/or stroke), showed that the incidence of MACE was 0/39 for placebo and 2/43 for lesinurad 200 mg.
Post-hoc analiza u podskupini bolesnika s visokim kardiovaskularnim rizikom na početku ispitivanja (definirano kao prolazni ishemijski napad, angina pektoris, zatajenje srca, infarkt miokarda, periferna vaskularna bolest i/ili moždani udar), pokazala je da je incidencija MACE bila 0/39 za placebo i 2/43 za lesinurad 200 mg.
Allopurinol is a xanthine-oxidase inhibitor.
Alopurinol je inhibitor ksantin oksidaze.
Oxypurinol is a less potent inhibitor of xanthine oxidase than allopurinol, but the plasma half-life of oxypurinol is far more prolonged.
Oksipurinol je manje potentan inhibitor ksantin oksidaze od alopurinola, ali je poluvijek oksipurinola u plazmi puno duži.
The effect of lesinurad and allopurinol on fertility in humans has not been studied.
Nije ispitan učinak lesinurada i alopurinola na plodnost u ljudi.
Allopurinol and its main metabolite oxypurinol lower the level of uric acid in plasma and urine by inhibition of xanthine oxidase, the enzyme catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid.
Alopurinol i njegov glavni metabolit oksipurinol snizuju razinu mokraćne kiseline u plazmi i urinu putem inhibicije ksantin oksidaze, enzima koji katalizira oksidaciju hipoksantina u ksantin i ksantina u mokraćnu kiselinu.
Patients known to be CYP2C9 poor metabolisers should be treated with caution, as the potential risk of lesinurad renal-related adverse reactions may be increased (see sections 4.8 and 5.2).
Potrebno je s oprezom liječiti bolesnike za koje je poznato da su spori CYP2C9 metabolizatori, jer mogući rizik od nuspojava lesinurada povezanih s bubrezima može biti povećan (vidjeti dijelove 4.8 i 5.2).
Extensive studies of high oral doses of allopurinol in mice up to 100 mg/kg/day, rats up to 200 mg/kg/day and rabbits up to 150 mg/kg/day during days 8 to 16 of gestation produced no teratogenic effects
Opsežna ispitivanja visokih oralnih doza alopurinola na miševima do 100 mg/kg/dan, štakorima do 200 mg/kg/dan i kunićima do 150 mg/kg/dan tijekom 8. do 16. dana gestacije nisu proizvela teratogene učinke.
Lesinurad when added to allopurinol caused a reduction of the mean serum uric acid levels, as compared to placebo, which was sustained in the long term in those patients who continued treatment (see Figure 1).
Kada se lesinurad primijenio zajedno s alopurinolom uzrokovao je smanjenje srednje razine mokraćne kiseline u serumu, u usporedbi s placebom, koje je bilo dugoročno održano u onih bolesnika koji su nastavili liječenje (vidjeti Sliku 1).
Patients with normal renal function will gradually accumulate oxypurinol until a steadystate plasma oxypurinol concentration is reached.
Bolesnici s normalnom funkcijom bubrega postepeno će nakupljati oksipurinol sve dok se ne postigne stanje dinamičke ravnoteže za koncentraciju oksipurinola u plazmi.
Patients continued their allopurinol dose and were randomised 1:1:1 to receive lesinurad 200 mg, lesinurad 400 mg, or placebo once daily.
Bolesnici su nastavili uzimati svoju dozu alopurinola i randomizirani su u omjeru 1:1:1 za primjenu lesinurada 200 mg, lesinurada 400 mg ili placeba jedanput dnevno.
If you forget to take Duzallo
Ako ste zaboravili uzeti Duzallo
Tissue concentrations of allopurinol have not been reported in humans, but it is likely that allopurinol and oxypurinol will be present in the highest concentrations in the liver and intestinal mucosa where xanthine oxidase activity is high.
Koncentracije alopurinola u tkivima nisu zabilježene u ljudi, ali je vjerojatno da su alopurinol i oksipurinol u najvećim koncentracijama prisutni u jetri i sluznici tankog crijeva gdje je visoka aktivnost ksantin oksidaze.
Hypersensitivity reactions to allopurinol may be increased in patients with decreased renal function receiving diuretics (in particular thiazides) and Duzallo concurrently (see sections 4.5 and 4.8).
Reakcije preosjetljivosti na alopurinol mogu se povećati u bolesnika sa smanjenom funkcijom bubrega koji istodobno primaju diuretike (naročito tiazide) i Duzallo (vidjeti dijelove 4.5 i 4.8).
10 film-coated tablets 30 film-coated tablets 100 film-coated tablets
10 filmom obloženih tableta 30 filmom obloženih tableta 100 filmom obloženih tableta
Cataract, vision disorders (visual impairment and blurred vision), maculopathy
Katarakta, poremećaji vida (oštećenje vida i mutan vid), makulopatija
Treatment with lesinurad 200 mg in combination with allopurinol was associated with an increased incidence of serum creatinine elevations, which are related to increased renal uric acid excretion.
Kombinirano liječenje lesinuradom u dozi od 200 mg i alopurinolom bilo je povezano s povećanom incidencijom povišenja serumskog kreatinina, koje je povezano s povećanim izlučivanjem mokraćne kiseline bubrezima.
Particularly in the case of a co-administration with azathioprine or 6mercaptopurine, absorption-reducing or elimination-increasing measures such as haemodialysis are indicated (haemodialysis may be considered in patients with severe renal or hepatic impairment).
Naročito u slučaju istodobne primjene azatioprina ili 6-merkaptopurina, indicirane su mjere za smanjenje apsorpcije ili povećanje eliminacije poput hemodijalize (hemodijaliza se može razmotriti u bolesnika s teškim oštećenjem funkcije bubrega ili jetre).
Oxypurinol, the major metabolite of allopurinol and itself therapeutically active, is excreted by the kidney in a similar way to urate.
Oksipurinol, glavni metabolit alopurinola i terapijski djelatna tvar, izlučuje se putem bubrega na sličan način kao urat.
Pack sizes of 10, 30 or 100 film-coated tablets.
Veličine pakiranja od 10, 30 ili 100 filmom obloženih tableta.
Elimination of allopurinol is mainly by metabolic conversion to oxypurinol by xanthine oxidase and aldehyde oxidase, with less than 10% of the unchanged active substance excreted in the urine.
Eliminacija alopurinola uglavnom se odvija metaboličkom konverzijom u oksipurinol pomoću ksantin oksidaze i aldehid oksidaze pri čemu se manje od 10% nepromijenjene djelatne tvari izlučuje putem mokraće.
Allopurinol and its metabolite oxypurinol are excreted in human breast milk.
Alopurinol i njegov metabolit oksipurinol se izlučuju u mlijeko liječenih žena.
Gout flares may occur after initiation of therapy with Duzallo.
Akutni napadaji gihta mogu se javiti nakon započinjanja terapije lijekom Duzallo.
Patients with serum creatinine elevations to greater than 1.5 times the pre-treatment value should be closely monitored.
Potrebno je pomno pratiti bolesnike u kojih je povišenje serumskog kreatinina veće od 1,5 puta u odnosu na vrijednost prije liječenja.
Patients who are currently treated with allopurinol doses higher than 300 mg can be switched to Duzallo 200 mg/200 mg or Duzallo 300 mg/200 mg and should receive complementary doses of allopurinol to cover the total dose of allopurinol taken before switching to Duzallo.
Bolesnici koji se trenutno liječe alopurinolom u dozama višim od 300 mg, mogu prijeći na Duzallo 200 mg/200 mg ili Duzallo 300 mg/200 mg i moraju primiti komplementarne doze alopurinola radi pokrivanja ukupne doze alopurinola koji se uzimao prije prijelaza na Duzallo.
The efficacy of lesinurad 200 mg once daily was studied in 2 multicentre, randomised, double-blind, placebo-controlled clinical studies in 812 adult patients (11% of these patients were elderly, ≥65 years old) with hyperuricaemia and gout in combination with allopurinol (CLEAR1 and CLEAR2).
Djelotvornost lesinurada u dozi od 200 mg jedanput dnevno ispitana je u 2 multicentrična, randomizirana, dvostruko slijepa, placebom kontrolirana klinička ispitivanja u 812 odraslih bolesnika (11% ovih bolesnika bili su starije osobe, u dobi od ≥ 65 godina) s hiperuricemijom i gihtom, u kombinaciji s alopurinolom (CLEAR1 i CLEAR2).
An increased risk of hypersensitivity has been reported when allopurinol is given with diuretics, in particular thiazides, especially in renal impairment (see section 4.4 and section 5.1).
Prijavljen je povećani rizik od preosjetljivosti kada se alopurinol daje s diureticima, naročito tiazidima, osobito u slučaju oštećenja funkcije bubrega (vidjeti dio 4.4 i dio 5.1).
No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh classes A and B) (see section 5.2).
Nije potrebna prilagodba doze u bolesnika s blagim ili umjerenim oštećenjem funkcije jetre (Child-Pugh stadij A ili B) (vidjeti dio 5.2).
The choice of the dose strength of Duzallo depends on the allopurinol dose taken as individual tablet(s).
Odabir jačine doze lijeka Duzallo ovisi o dozi alopurinola koji se uzima kao pojedinačna(e) tableta(e).
Other metabolites of allopurinol include allopurinol-riboside and oxypurinol-7-riboside.
Drugi metaboliti alopurinola uključuju alopurinol-ribozid i oksipurinol-7-ribozid.
Hormonal contraception (this includes oral, injectable, transdermal, and implantable forms) might not be reliable when taking Duzallo at the same time.
Hormonska kontracepcija (to uključuje oralne, injekcijske, transdermalne oblike i implantate) može biti nepouzdana kada se u isto vrijeme uzima Duzallo.
Duzallo is indicated in adults for the treatment of hyperuricaemia in gout patients who have not achieved target serum uric acid levels with an adequate dose of allopurinol alone.
Duzallo je indiciran za liječenje hiperuricemije u bolesnika s gihtom koji nisu postigli ciljne razine mokraćne kiseline u serumu uz liječenje samo alopurinolom u odgovarajućoj dozi.
Patients with renal impairment, where creatinine clearance values were between 10 and 20 ml/min, showed plasma oxypurinol concentrations of approximately 30 mg/litre after prolonged treatment with 300 mg allopurinol per day.
Bolesnici s oštećenjem funkcije bubrega, čije su vrijednosti klirensa kreatinina iznosile između 10 i 20 ml/min, pokazali su koncentracije oksipurinola u plazmi od približno 30 mg/litri nakon produljenog liječenja dozom od 300 mg alopurinola dnevno.
Mild to moderate induction of CYP3A by lesinurad may reduce plasma exposures of co-administered medicinal products that are sensitive substrates of CYP3A.
Blaga do umjerena indukcija CYP3A lesinuradom može smanjiti izloženost istodobno primjenjivanim lijekovima u plazmi, koji su osjetljivi supstrati CYP3A.
How to take Duzallo
Kako uzimati Duzallo
Pharmacotherapeutic group: Antigout preparations, preparations inhibiting uric acid production.
Farmakoterapijska skupina: Pripravci za liječenje gihta, pripravci koji inhibiraju stvaranje mokraćne kiseline.
Duzallo which contains lesinurad as active substance causes an increase in renal uric acid excretion, which may lead to transient increases in serum creatinine, renal-related adverse reactions and kidney stones (see section 5.1).
Duzallo koji sadrži lesinurad kao djelatnu tvar, uzrokuje pojačano izlučivanje mokraćne kiseline bubrezima, što može dovesti do prolaznih povišenja razine serumskog kreatinina, nuspojava povezanih s bubrezima i bubrežnih kamenaca (vidjeti dio 5.1).
Lesinurad is not an in vitro inhibitor of P-glycoprotein, BCRP, OATP1B3, MRP2, MRP4, OCT2, MATE1, MATE2-K and BSEP.
Lesinurad nije in vitro inhibitor P-glikoproteina, BCRP, OATP1B3, MRP2, MRP4, OCT2, MATE1, MATE2-K i BSEP.
Clinical outcomes - concomitant use of thiazides
Klinički ishodi - istodobna primjena tiazida
Common - may affect up to 1 in 10 people - increased level of thyroid stimulating hormone in the blood, - flu, - headache, - blood tests showing increased creatinine (which may be a sign of kidney problems), - heartburn (acid reflux), - skin rash.
Često - mogu se javiti u do 1 na 10 osoba - povećana razina hormona u krvi koji stimulira štitnjaču, - gripa, - glavobolja, - krvne pretrage koje pokazuju povišeni kreatinin (što može biti znak problema s bubrezima), - žgaravica (vraćanje kiseline), - kožni osip.
In the long-term uncontrolled extension trials, the rates of gout flares requiring treatment further decreased in the 60% of subjects who entered the extension studies and continued treatment with lesinurad 200 mg in combination with allopurinol or febuxostat for up to an additional year of treatment.
U dugotrajnim, nekontroliranim nastavcima ispitivanja, stope akutnih napadaja gihta koje je potrebno liječiti dodatno su se smanjile u 60% ispitanika koji su bili uključeni u nastavke ispitivanja i nastavili liječenje lesinuradom 200 mg u kombinaciji s alopurinolom ili febuksostatom tijekom dodatne godine liječenja.
Lesinurad undergoes oxidative metabolism mainly via cytochrome P450 (CYP) 2C9 to intermediate metabolite M3c (not detected in vivo) and is subsequently metabolised by microsomal epoxide hydrolase (mEH) to metabolite M4; there is minimal contribution from CYP1A1, CYP2C19, and CYP3A to the metabolism of lesinurad.
Oksidativni metabolizam lesinurada uglavnom se odvija putem citokroma P450 (CYP) 2C9, do intermedijarnog metabolita M3c (nije otkriven in vivo) koji se naknadno metabolizira putem mikrosomalne epoksid hidrolaze (mEH) do metabolita M4; doprinos CYP1A1, CYP2C19 i CYP3A metabolizmu lesinurada je minimalan.